
|Videos|November 6, 2018
Immunotherapy Potential in Locally Advanced CSCC
Immunotherapy Potential in Locally Advanced CSCC
Advertisement
A 69-Year-Old Man With Advanced CSCC
- History and physical exam
- An otherwise healthy, 69-year-old male, fair skinned, retired construction worker, widow
- Presented to his PCP with what he described as a wound that was not healing behind his ear; he reported first noticing it at least 6 months ago and complained of recent onset of numbness in the area.
- ECOG PS 1
- The visible, ulcerated lesion was 4.5-cm in diameter and >5-mm deep
- No palpable nodes
- Biopsy confirmed a poorly-differentiated, infiltrative, postauricular cutaneous squamous cell carcinoma lesion with 7-mm invasion into subcutaneous fat.
- The recommended definitive surgical approach involved partial auriculectomy; the patient declined.
- Cemiplimab 3 mg/kg q2w was initiated
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5







































